Pharmacokinetics and pharmacodynamics of recombinant proteins and peptides
- 31 March 1994
- journal article
- Published by Elsevier BV in Journal of Controlled Release
- Vol. 29 (3), 269-281
- https://doi.org/10.1016/0168-3659(94)90073-6
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- The Role of Pharmacokinetics in the Development of Biotechnologically Derived AgentsClinical Pharmacokinetics, 1992
- Characterization of human tissuetype plasminogen activator variants with amino acid mutations in the kringle 1 domainBlood Coagulation & Fibrinolysis, 1992
- ATRIAL NATRIURETIC FACTOR AND RELATED PEPTIDE HORMONESAnnual Review of Biochemistry, 1991
- Pulmonary extraction of immunoreactive atrial natriuretic factor in dogsThe American Journal of Cardiology, 1989
- A Modified Human Tissue Plasminogen Activator with Extended Half–Life In VivoNature Biotechnology, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Man versus Beast: Pharmacokinetic Scaling in MammalsJournal of Pharmaceutical Sciences, 1986
- Intranasal administration of alpha-human natriuretic peptide produces a prolonged diuresis in healthy manLife Sciences, 1986
- The Thrombolysis in Myocardial Infarction (TIMI) TrialNew England Journal of Medicine, 1985
- Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial.Circulation, 1984